Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.51 |
| ▸ | MTOR | P42345 | 2/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | ATR | Q13535 | 2/20 | 0.50 |
| ▸ | ERN1 | O75460 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | JAK2 | O60674 | 3/20 | 0.48 |
| ▸ | JAK1 | P23458 | 2/20 | 0.48 |
| ▸ | TYK2 | P29597 | 2/20 | 0.48 |
| ▸ | JAK3 | P52333 | 2/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14090212 | 0.91 | PIK3CD (0.49) | MEN1KMT2APIK3CDMTORPIK3CA | |
| SCHEMBL14090220 | 0.91 | HDAC6 (0.51) | MEN1KMT2APIK3CDMTORPIK3CA | |
| SCHEMBL14090252 | 0.91 | ACACB (0.49) | MEN1KMT2APIK3CDMTORPIK3CA | |
| SCHEMBL14090263 | 0.89 | HDAC6 (0.49) | MEN1KMT2APIK3CDMTORPIK3CA | |
| SCHEMBL14090204 | 0.89 | FGFR1 (0.48) | MEN1KMT2APIK3CDMTORPIK3CA | |
| SCHEMBL14090386 | 0.86 | RIPK1 (0.48) | MEN1KMT2APIK3CDMTORPIK3CA | |
| SCHEMBL14090244 | 0.85 | MGLL (0.50) | MGLLCHEK2FGFR1KDRHDAC3 | |
| SCHEMBL14090236 | 0.85 | MEN1 (0.47) | MEN1KMT2APIK3CDMTORPIK3CA | |
| SCHEMBL14090342 | 0.83 | AMY1A (0.53) | MEN1KMT2APIK3CDMTORPIK3CA | |
| SCHEMBL14090227 | 0.83 | FGFR1 (0.49) | MEN1KMT2APIK3CDMTORPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629147-B2 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629147-B2 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2014-01-14 | — | — | US | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | LCK, MALT1, MYD88 | MEN1 1879/4885KMT2A 1726/4885PIK3CD 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.